var data={"title":"Griseofulvin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Griseofulvin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6285?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">see &quot;Griseofulvin: Drug information&quot;</a> and <a href=\"topic.htm?path=griseofulvin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Griseofulvin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177520\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Grifulvin V [DSC];</li>\n      <li>Gris-PEG</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047635\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047628\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">see &quot;Griseofulvin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing; susceptible infection</b> (<i>Red Book</i>, 2012): Oral: Children &gt;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Microsize: 10-20 mg/kg/day in single or 2 divided doses; maximum daily dose: 1000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ultramicrosize: 5-15 mg/kg/day once daily or in 2 divided doses; maximum daily dose: 750 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea capitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;1 month to Children &le;2 years:  Limited data available: 10 mg/kg/day in single or divided doses (Higgins, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;2 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Microsize:  20-25 mg/kg/day once daily (maximum daily dose 1000 mg/day) for 6-8 weeks or until fungal cultures clear; in some cases, treatment up to 16 weeks may be  necessary (Ali, 2007; Higgins, 2000, Kakourou, 2010, <i>Red Book</i>, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ultramicrosize: 10-15 mg/kg/day once daily (maximum daily dose 750 mg/day) for 6-8 weeks or until fungal cultures clear; in some cases, treatment up to 16 weeks may be  necessary (Ali, 2007; Higgins, 2000, Kakourou, 2010, <i>Red Book</i>, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea corporis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Microsize: 500 mg daily in single or divided doses for 2-4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ultramicrosize: 375 mg daily in single or divided doses for 2-4 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea cruris:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Microsize: 500 mg daily in single or divided doses 2-6 weeks (<i>Red Book</i>, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ultramicrosize: 375 mg daily in single or divided doses 2-6 weeks (<i>Red Book</i>, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea capitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Microsize: 500 mg daily in single or divided doses for 4-6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ultramicrosize: 375 mg daily in single or divided doses for 4-6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea pedis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Microsize: 1000 mg daily in single or divided doses for 4-8 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ultramicrosize: 375 mg daily in single or divided doses for 4-8 weeks ; doses up to 750 mg daily in divided doses have been used </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tinea unguium: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Microsize: 1000 mg daily in single or divided doses for 4-6 months or longer</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ultramicrosize: 375 mg daily in single or divided doses 4-6 months or longer; doses up to 750 mg daily in divided doses have been used </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112851\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112852\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">All patients: Use is contraindicated in hepatic failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177525\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">see &quot;Griseofulvin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatophyte infections:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Microsize:</i></b> 500 mg/day in single or divided doses; for more widespread lesions initial doses of 750 to 1,000 mg/day in single or divided doses may be needed; may decrease gradually to 500 mg/day or less if patient responds to higher dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Ultramicrosize:</b></i> 375 mg daily in single or divided doses; doses up to 750 mg/day in divided doses have been used for infections more difficult to eradicate such as tinea unguium and tinea pedis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Duration of therapy depends on the site of infection:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea corporis: 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea cruris: Duration not specified in manufacturer&rsquo;s labeling; in pediatric patients 6 weeks has been recommended (<i>Red Book</i>, 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea capitis: 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea pedis: 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tinea unguium: 4 to 6 months or longer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991858\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989154\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in hepatic failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177502\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (118 mL [DSC], 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Grifulvin V: 500 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gris-PEG: 125 mg, 250 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177487\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123828\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">see &quot;Griseofulvin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Microsized formulations: Suspensions, Grifulvin V tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ultramicrosize formulation: Gris-PEG tablets</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047638\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with a fatty meal (peanut butter or ice cream to increase absorption), or with food or milk to avoid GI upset; shake suspension well before use. Ultramicrosize tablets may be swallowed whole or crushed and sprinkled onto 1 tablespoonful of applesauce and taken immediately without chewing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15826199\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047637\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of tinea infections of the skin and hair caused by susceptible species of <i>Microsporum</i>, <i>Epidermophyton</i>, or <i>Trichophyton</i> (FDA approved in ages &gt;2 years and adults) when lesions are unresponsive to topical antifungal therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177563\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, dizziness, fatigue, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological reaction (erythema multiforme-like drug reaction), skin photosensitivity, skin rash (most common), urticaria (most common)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, epigastric distress, gastrointestinal hemorrhage, nausea, oral candidiasis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Granulocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, increased serum bilirubin, increased serum transaminases, leukopenia, lupus-like syndrome, paresthesia, proteinuria, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177508\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to griseofulvin or any component of the formulation; hepatic failure; porphyria; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177491\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Leukopenia has been reported (rare); discontinue therapy if granulocytopenia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: May cause jaundice and elevated liver function tests or bilirubin (may be serious or even fatal); monitor hepatic function and discontinue therapy if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Hypersensitivity cross reaction between penicillins and griseofulvin is possible, however, known penicillin-sensitive patients have been treated successfully without complications. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: Avoid exposure to intense sunlight to prevent photosensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) have been reported (may be serious or even fatal); discontinue use if severe skin reactions occur. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lupus erythematosus: Development of lupus erythematosus, lupus-like syndromes or exacerbation of existing lupus erythematosus has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use for the prophylaxis of fungal infections has not been established; not effective for the treatment of tinea versicolor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177554\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177496\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13342&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Griseofulvin may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Griseofulvin.<b> Exceptions: </b>Methohexital; Thiopental.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Griseofulvin may enhance the adverse/toxic effect of Carbocisteine. Specifically, griseofulvin may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Griseofulvin may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Griseofulvin may increase the metabolism of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Griseofulvin may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Griseofulvin may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Griseofulvin may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177516\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Concomitant use will cause a &quot;disulfiram&quot;-type reaction consisting of tachycardia, flushing, headache, nausea, and in some patients, vomiting and chest and/or abdominal pain. Management: Avoid ethanol consumption during therapy; if ethanol is consumed, monitor patients for signs of reaction. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Griseofulvin concentrations may be increased if taken with food, especially with high-fat meals. Management: Take with a fatty meal (peanuts or ice cream) to increase absorption, or with food or milk to avoid GI upset.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20503046\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4293494\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects have been observed in animal reproduction studies. Griseofulvin crosses the placenta (Pacifici, 2006). Because adverse events have also been observed in humans (two cases of conjoined twins), use during pregnancy is contraindicated. Effective contraception should be used during therapy and for 1 month after therapy is discontinued in women of reproductive potential.  Men should avoid fathering a child for at least 6 months after therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047634\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematopoietic function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177490\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits fungal cell mitosis at metaphase; binds to human keratin making it resistant to fungal invasion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177507\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Ultramicrosize griseofulvin absorption is almost complete; absorption of microsize griseofulvin is variable (27% to 72% of an oral dose); enhanced by ingestion of a fatty meal (GI absorption of ultramicrosize is ~1.5 times that of microsize); absorbed from the duodenum</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Deposited in the keratin layer of skin, hair, and nails; concentrates in liver, fat, and skeletal muscles; V<sub>d</sub>: ~1.5  L (Vozeh 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 9 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1% as unchanged drug); feces (~33%); perspiration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177510\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Griseofulvin Microsize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (120 mL): $78.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gris-PEG Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $620.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $791.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Griseofulvin Microsize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $850.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Griseofulvin Ultramicrosize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $478.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $611.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177511\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afuvin (BD);</li>\n      <li>Asfulvin (LK);</li>\n      <li>Biogrisin (PL);</li>\n      <li>Delmofulvina (IT);</li>\n      <li>Fulcin (BR, EC, FI, IT, NO, PT, QA);</li>\n      <li>Fulcin Forte (MX);</li>\n      <li>Fulcin S (DE);</li>\n      <li>Fulcinex (BD);</li>\n      <li>Fulsovin (GB);</li>\n      <li>Fulvin G (BD);</li>\n      <li>Fungistop (ID);</li>\n      <li>Fungivin (NO, PK);</li>\n      <li>Fusovin (TH);</li>\n      <li>Gricin (CZ, DE, HU, PL);</li>\n      <li>Grifulin Forte (IL);</li>\n      <li>Grifulvin (TH);</li>\n      <li>Grisefuline (FR);</li>\n      <li>Grisen (TW);</li>\n      <li>Grisenova (GR);</li>\n      <li>griseo von ct (DE);</li>\n      <li>Griseofil (LK);</li>\n      <li>Griseofulvin (IE, PL);</li>\n      <li>Griseofulvin Leo (LU);</li>\n      <li>Griseofulvin Prafa (ID);</li>\n      <li>Griseofulvina (IT);</li>\n      <li>Griseomed (AT);</li>\n      <li>Griseovin (EG);</li>\n      <li>Griseovine (VN);</li>\n      <li>Grisflavin (TH);</li>\n      <li>Grisfulvin V (PH);</li>\n      <li>Grisol (CH);</li>\n      <li>Grisomicon (PT);</li>\n      <li>Grisoral (IN);</li>\n      <li>Grisovin (AE, AT, AU, BH, CO, CR, CY, CZ, DO, EG, GT, HN, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PE, PT, QA, SA, SV, SY, VE, YE);</li>\n      <li>Grisovin F.P. (LK);</li>\n      <li>Grisovin-FP (AR, PH, UY);</li>\n      <li>Grisovina FP (IT);</li>\n      <li>Grisuven (HK);</li>\n      <li>Grisuvin (MY);</li>\n      <li>Grivin (MY, TH);</li>\n      <li>Grivin Forte (ID);</li>\n      <li>Japcin (BD);</li>\n      <li>Krisovin (MY, SG);</li>\n      <li>Likuden (DE);</li>\n      <li>Microcidal (ZA);</li>\n      <li>Pongyl V (KR);</li>\n      <li>Ponzyr V (KR);</li>\n      <li>Rexavin (ID);</li>\n      <li>Trivanex (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ali S, Graham TA, and Forgie SE, &quot;The Assessment and Management of Tinea Capitis in Children,&quot; <i>Pediatr Emerg Care</i>, 2007,  23(9):662-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/17876261/pubmed\" target=\"_blank\" id=\"17876261\">17876261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleece D, Gaughan JP, and Aronoff SC, &quot;Griseofulvin Versus Terbinafine in the Treatment of Tinea Capitis: A Meta-Analysis of Randomized, Clinical Trials,&quot; <i>Pediatrics</i>, 2004, 114(5):1312-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/15520113/pubmed\" target=\"_blank\" id=\"15520113\">15520113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ginsburg CM, McCracken GH Jr, Petruska M, et al, &ldquo;Effect of Feeding on Bioavailability of Griseofulvin in Children,&rdquo; <i>J Pediatr</i>, 1983, 102(2):309-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/6822943/pubmed\" target=\"_blank\" id=\"6822943\">6822943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Adam P, Dlova N, et al, &quot;Therapeutic Options for the Treatment of Tinea Capitis Caused by <i>Trichophyton</i> Species: Griseofulvin Versus the New Oral Antifungal Agents, Terbinafine, Itraconazole, and Fluconazole,&quot; <i>Pediatr Dermatol</i>, 2001,  18(5):433-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/11737692/pubmed\" target=\"_blank\" id=\"11737692\">11737692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Ryder JE, Nicol K, et al, &quot;Superficial Fungal Infections: An Update on Pityriasis Versicolor, Seborrheic Dermatitis, Tinea Capitis, and Onychomycosis,&quot; <i>Clin Dermatol</i>, 2003, 21(5):417-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/14678722/pubmed\" target=\"_blank\" id=\"14678722\">14678722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higgins EM, Fuller LC, and Smith CH, &quot;Guidelines for the Management of Tinea Capitis. British Association of Dermatologists,&quot; <i>Br J Dermatol</i>, 2000,  143(1):53-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/10886135/pubmed\" target=\"_blank\" id=\"10886135\">10886135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kakourou T and Uksal U, &quot;Guidelines for the Management of Tinea Capitis in Children,&quot; <i>Pediatr Dermatol</i>, 2010, 27(3):226-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/20609140/pubmed\" target=\"_blank\" id=\"20609140\">20609140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipozencic J, Skerlev M, Orofino-Costa R, et al, &quot;A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study of Oral Terbinafine and Open-Label, High-Dose Griseofulvin in Children With Tinea Capitis Due to <i>Microsporum</i> Species,&quot; <i>Br J Dermatol</i>, 2002, 146(5):816-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/12000378/pubmed\" target=\"_blank\" id=\"12000378\">12000378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacifici GM, &quot;Placental Transfer of Antibiotics Administered to the Mother: A Review,&quot;  <i>Int J Clin Pharmacol Ther</i>,  2006, 44(2):57-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/16502764/pubmed\" target=\"_blank\" id=\"16502764\">16502764</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sethi A and Antaya R, &quot;Systemic Antifungal Therapy for Cutaneous Infections in Children,&quot; <i>Pediatr Infect Dis J</i>, 2006, 25(7):643-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/16804437/pubmed\" target=\"_blank\" id=\"16804437\">16804437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, and Taeschner W, &quot;Pharmacokinetic Drug Data,&quot; <i>Clin Pharmacokinet</i>, 1988, 15(4):254-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/griseofulvin-pediatric-drug-information/abstract-text/3191648/pubmed\" target=\"_blank\" id=\"3191648\">3191648</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13342 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F177520\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047635\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1047628\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112851\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112852\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177525\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991858\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989154\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F177502\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F177487\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22123828\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047638\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F15826199\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047637\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177563\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177508\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177491\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F177554\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F177496\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F177516\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F20503046\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4293494\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047634\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F177490\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F177507\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F177510\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F177511\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13342|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">Griseofulvin: Drug information</a></li><li><a href=\"topic.htm?path=griseofulvin-patient-drug-information\" class=\"drug drug_patient\">Griseofulvin: Patient drug information</a></li></ul></div></div>","javascript":null}